Ex­clu­sive: Eli Lil­ly sup­plied schiz­o­phre­nia drug to un­cer­ti­fied health­care providers, Form 483 shows

Eli Lil­ly shipped its schiz­o­phre­nia drug to un­cer­ti­fied phar­ma­cies and was not ad­her­ing to es­tab­lished safe­ty pro­ce­dures, the FDA found af­ter a Sep­tem­ber in­spec­tion at the com­pa­ny’s cor­po­rate of­fices in In­di­ana.

The agency not­ed five de­fi­cien­cies in­volv­ing Zyprexa Rel­prevv, in which the com­pa­ny did not fol­low the ap­proved Risk Eval­u­a­tion and Mit­i­ga­tion Strat­e­gy (REMS), a pro­gram for drugs with se­ri­ous safe­ty con­cerns, ac­cord­ing to a Form 483 ob­tained by End­points News through a FOIA re­quest.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER